- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - ASTRAZENECA PHARMA
DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results
DISHMAN PHARMA 
Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
ASTRAZENECA PHARMA
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| DISHMAN PHARMA | ASTRAZENECA PHARMA | DISHMAN PHARMA/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | 97.8 | 25.7% | View Chart |
| P/BV | x | 3.3 | 27.3 | 12.3% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 DISHMAN PHARMA  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
ASTRAZENECA PHARMA Mar-14 |
DISHMAN PHARMA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 1,285 | 29.1% | |
| Low | Rs | 129 | 634 | 20.3% | |
| Sales per share (Unadj.) | Rs | 197.8 | 189.6 | 104.3% | |
| Earnings per share (Unadj.) | Rs | 21.2 | -0.2 | -10,415.4% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 3.8 | 903.2% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 68.6 | 262.1% | |
| Shares outstanding (eoy) | m | 80.69 | 25.00 | 322.8% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 5.1 | 25.1% | |
| Avg P/E ratio | x | 11.9 | -4,712.7 | -0.3% | |
| P/CF ratio (eoy) | x | 7.2 | 249.6 | 2.9% | |
| Price / Book Value ratio | x | 1.4 | 14.0 | 10.0% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 23,988 | 84.7% | |
| No. of employees | `000 | 0.8 | 1.6 | 53.2% | |
| Total wages/salary | Rs m | 5,355 | 1,605 | 333.7% | |
| Avg. sales/employee | Rs Th | 19,252.7 | 3,040.2 | 633.3% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 1,029.2 | 627.6% | |
| Avg. net profit/employee | Rs Th | 2,064.1 | -3.3 | -63,219.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 4,740 | 336.7% | |
| Other income | Rs m | 265 | 92 | 288.2% | |
| Total revenues | Rs m | 16,226 | 4,832 | 335.8% | |
| Gross profit | Rs m | 4,103 | -130 | -3,161.2% | |
| Depreciation | Rs m | 1,091 | 101 | 1,077.7% | |
| Interest | Rs m | 944 | 0 | - | |
| Profit before tax | Rs m | 2,334 | -139 | -1,680.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 139 | 0.0% | |
| Tax | Rs m | 624 | 5 | 12,251.5% | |
| Profit after tax | Rs m | 1,711 | -5 | -33,616.9% | |
| Gross profit margin | % | 25.7 | -2.7 | -938.8% | |
| Effective tax rate | % | 26.7 | -3.7 | -729.2% | |
| Net profit margin | % | 10.7 | -0.1 | -9,983.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 2,726 | 404.1% | |
| Current liabilities | Rs m | 9,517 | 2,435 | 390.8% | |
| Net working cap to sales | % | 9.4 | 6.1 | 153.0% | |
| Current ratio | x | 1.2 | 1.1 | 103.4% | |
| Inventory Days | Days | 110 | 74 | 149.8% | |
| Debtors Days | Days | 35 | 41 | 85.5% | |
| Net fixed assets | Rs m | 16,304 | 1,035 | 1,574.8% | |
| Share capital | Rs m | 161 | 50 | 322.8% | |
| "Free" reserves | Rs m | 12,907 | 942 | 1,369.6% | |
| Net worth | Rs m | 14,516 | 1,716 | 845.9% | |
| Long term debt | Rs m | 4,189 | 0 | - | |
| Total assets | Rs m | 29,805 | 4,156 | 717.2% | |
| Interest coverage | x | 3.5 | NM | - | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 1.1 | 47.0% | |
| Return on assets | % | 8.9 | -0.1 | -7,274.7% | |
| Return on equity | % | 11.8 | -0.3 | -3,974.1% | |
| Return on capital | % | 17.5 | 0 | - | |
| Exports to sales | % | 24.8 | 5.7 | 434.8% | |
| Imports to sales | % | 3.7 | 6.5 | 57.8% | |
| Exports (fob) | Rs m | 3,956 | 270 | 1,464.2% | |
| Imports (cif) | Rs m | 596 | 306 | 194.7% | |
| Fx inflow | Rs m | 4,952 | 375 | 1,321.8% | |
| Fx outflow | Rs m | 697 | 470 | 148.2% | |
| Net fx | Rs m | 4,255 | -96 | -4,452.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | -8 | -34,400.0% | |
| From Investments | Rs m | -1,529 | -146 | 1,049.3% | |
| From Financial Activity | Rs m | -941 | 862 | -109.2% | |
| Net Cashflow | Rs m | 316 | 709 | 44.7% | |
Share Holding
| Indian Promoters | % | 61.4 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 0.3 | 1,233.3% | |
| FIIs | % | 12.7 | 15.7 | 80.9% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 9.1 | 242.9% | |
| Shareholders | 46,261 | 12,856 | 359.8% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: FULFORD INDIA VENUS REMEDIES STERLING BIOTECH WOCKHARDT LTD. SUVEN LIFE
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Recapitalisation Package for PSBs: The Pros & Cons(Podcast)
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)
Aug 21, 2018 | Updated on Aug 21, 2018For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Feb 12, 2019Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 8-QTR ANALYSIS
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.